Julie O'DOnnell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julie O'DOnnell has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
R. Matt Gladden
Centers for Disease Control and Prevention National Center for Injury Prevention and Control, Division of Overdose Prevention Atlanta GA USA
6 shared publicationsChristine L. Mattson
5 shared publicationsMbabazi Kariisa
Centers for Disease Control and Prevention National Center for Injury Prevention and Control, Division of Overdose Prevention Atlanta GA USA
3 shared publicationsR. Matthew Gladden
Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC
3 shared publicationsCalli T. Hunter
Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Division of Overdose Prevention, 4770 Buford Hwy, Atlanta, GA 30341, USA
2 shared publicationsFarnaz Chowdhury
Peers and Partners, Inc., Seattle, Washington, USA
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in American Journal of Preventive Medicine
Availability of Toxicology Testing Results Among Drug Overdose Deaths, U.S., 2020–2024
- 29 September 2026
- Published by Elsevier in American Journal of Preventive Medicine
Open AccessAvailability of Toxicology Testing Results Among Drug Overdose Deaths, U.S., 2020–2024
- 1 September 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (35) , 949-956
Drug Overdose Deaths with Evidence of Counterfeit Pill Use — United States, July 2019–December 2021
This report describes trends in overdose deaths with evidence of counterfeit pill use from July–September 2019 to October–December 2021.
- 1 September 2023
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 72 (35) , 949-956
Drug Overdose Deaths with Evidence of Counterfeit Pill Use — United States, July 2019–December 2021
This report describes trends in overdose deaths with evidence of counterfeit pill use from July–September 2019 to October–December 2021.
Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018–December 2019
Background and Aims: Tracking specific drugs contributing to drug overdose deaths is limited when relying on death certificate (DC) data alone. This study aimed to determine whether integrating DC data with medical examiner/coroner reports, including postmortem toxicology and death investigation findings, would enhance identification of (1) heroin and pharmaceutical morphine involvement in overdose deaths and (2) fentanyl source (illicitly manufactured versus pharmaceutical).Design: Retrospective analysis of heroin, pharmaceutical morphine, illicitly manufactured fentanyl (IMF) and pharmaceutical fentanyl involvement in fatal overdoses. DC and toxicology data were compared with enhanced definitions integrating overdose scene, witness and toxicology evidence.Setting: United States: 38 states and the District of Columbia, participating in Centers for Disease Control and Prevention (CDC)‐funded opioid overdose death surveillance.Cases: Opioid overdose decedents from funded jurisdictions; deaths during 1 January 2018–31 December 2019.Measurements: Using medical examiner/coroner report data, deaths with 6‐acetylmorphine and/or morphine detected by postmortem toxicology were defined as confirmed, probable or suspected heroin deaths, or probable pharmaceutical morphine deaths. Fentanyl was defined as probable or suspected IMF or probable pharmaceutical fentanyl.Findings: The enhanced definition defined 18 393 deaths as confirmed, probable, or suspected heroin deaths (including 2678 with morphine listed as cause of death on the DC) and 404 as probable pharmaceutical morphine deaths. Among deaths with fentanyl detected, 89.3% were defined as probable or suspected IMF and 1.0% as probable pharmaceutical fentanyl. Fentanyl source could not be determined for 9.7% of deaths.Conclusions: Integrating drug overdose scene, witness and toxicology findings can improve identification of specific drugs contributing to overdose deaths and enhance overdose intervention targeting.
Using death scene and toxicology evidence to define involvement of heroin, pharmaceutical morphine, illicitly manufactured fentanyl and pharmaceutical fentanyl in opioid overdose deaths, 38 states and the District of Columbia, January 2018–December 2019
Background and Aims: Tracking specific drugs contributing to drug overdose deaths is limited when relying on death certificate (DC) data alone. This study aimed to determine whether integrating DC data with medical examiner/coroner reports, including postmortem toxicology and death investigation findings, would enhance identification of (1) heroin and pharmaceutical morphine involvement in overdose deaths and (2) fentanyl source (illicitly manufactured versus pharmaceutical).Design: Retrospective analysis of heroin, pharmaceutical morphine, illicitly manufactured fentanyl (IMF) and pharmaceutical fentanyl involvement in fatal overdoses. DC and toxicology data were compared with enhanced definitions integrating overdose scene, witness and toxicology evidence.Setting: United States: 38 states and the District of Columbia, participating in Centers for Disease Control and Prevention (CDC)‐funded opioid overdose death surveillance.Cases: Opioid overdose decedents from funded jurisdictions; deaths during 1 January 2018–31 December 2019.Measurements: Using medical examiner/coroner report data, deaths with 6‐acetylmorphine and/or morphine detected by postmortem toxicology were defined as confirmed, probable or suspected heroin deaths, or probable pharmaceutical morphine deaths. Fentanyl was defined as probable or suspected IMF or probable pharmaceutical fentanyl.Findings: The enhanced definition defined 18 393 deaths as confirmed, probable, or suspected heroin deaths (including 2678 with morphine listed as cause of death on the DC) and 404 as probable pharmaceutical morphine deaths. Among deaths with fentanyl detected, 89.3% were defined as probable or suspected IMF and 1.0% as probable pharmaceutical fentanyl. Fentanyl source could not be determined for 9.7% of deaths.Conclusions: Integrating drug overdose scene, witness and toxicology findings can improve identification of specific drugs contributing to overdose deaths and enhance overdose intervention targeting.
- Top Cited PapersOpen Access
- 17 December 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (50) , 1740-1746
Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020
This report describes drug overdose deaths from illicitly manufactured fentanyls during 2019–2020
- 17 December 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (50) , 1740-1746
Top Cited PapersOpen AccessTrends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020
This report describes drug overdose deaths from illicitly manufactured fentanyls during 2019–2020
- Open Access
- 1 November 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3794-3800
Trends in nonfatal and fatal overdoses involving benzodiazepines—38 states and the District of Columbia, 2019–2020
- 1 November 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3794-3800
Open AccessTrends in nonfatal and fatal overdoses involving benzodiazepines—38 states and the District of Columbia, 2019–2020
- Top Cited PapersOpen Access
- 27 August 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (34) , 1136-1141
Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020
This report describes trends in overdoses involving benzodiazepines during 2019–2020.
- 27 August 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (34) , 1136-1141
Top Cited PapersOpen AccessTrends in Nonfatal and Fatal Overdoses Involving Benzodiazepines — 38 States and the District of Columbia, 2019–2020
This report describes trends in overdoses involving benzodiazepines during 2019–2020.
- Top Cited Papers
- 4 September 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (35) , 1189-1197
Vital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019
This report describes characteristics of drug overdose deaths that involved opioids and stimulants during 2019 and how changes to prevention, treatment, and response strategies could help prevent overdose deaths.
- 4 September 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (35) , 1189-1197
Top Cited PapersVital Signs: Characteristics of Drug Overdose Deaths Involving Opioids and Stimulants — 24 States and the District of Columbia, January–June 2019
This report describes characteristics of drug overdose deaths that involved opioids and stimulants during 2019 and how changes to prevention, treatment, and response strategies could help prevent overdose deaths.
- 13 March 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (10) , 271-273
Notes from the Field: Opioid-Involved Overdose Deaths with Fentanyl or Fentanyl Analogs Detected — 28 States and the District of Columbia, July 2016–December 2018
The declines in overdose deaths with fentanyl analogs (carfentanil, furanylfentanyl, acrylfentanyl, and cyclopropylfentanyl) detected contributed to declines in opioid-involved overdose deaths during 2018 among a subset of states, even as deaths with fentanyl detected increased over time, which highlights the continued need to test for fentanyl analogs.
- 13 March 2020
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 69 (10) , 271-273
Notes from the Field: Opioid-Involved Overdose Deaths with Fentanyl or Fentanyl Analogs Detected — 28 States and the District of Columbia, July 2016–December 2018
The declines in overdose deaths with fentanyl analogs (carfentanil, furanylfentanyl, acrylfentanyl, and cyclopropylfentanyl) detected contributed to declines in opioid-involved overdose deaths during 2018 among a subset of states, even as deaths with fentanyl detected increased over time, which highlights the continued need to test for fentanyl analogs.
- 18 January 2019
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 68 (2) , 41-43
Notes from the Field: Fentanyl Drug Submissions — United States, 2010–2017
In 2017, the United States recorded 70,237 drug overdose deaths; among these, 47,600 (67.8%) involved an opioid and 28,466 (40.5%) involved a synthetic opioid other than methadone.
- 18 January 2019
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 68 (2) , 41-43
Notes from the Field: Fentanyl Drug Submissions — United States, 2010–2017
In 2017, the United States recorded 70,237 drug overdose deaths; among these, 47,600 (67.8%) involved an opioid and 28,466 (40.5%) involved a synthetic opioid other than methadone.